Cancer Genetics (CGI) has announced today that India-based Kamineni Hospitals has introduced CGI's FHACT diagnostic test for the detection and management of cervical cancer.
This is the first broad-scale adoption of the genomic test in India where cervical cancer is the most prevalent cancer affecting women.
CGI’s FISH-Based HPV-Associated Cancer Test (FHACT) assesses genomic alterations commonly observed in cervical pre-cancer and cancer upon infection and persistence of HPV. FHACT is a unique DNA FISH probe combination of four genomic biomarkers that can be used on remnant liquid Pap cytology or on conventional Pap smear.
This launch culminates a collaboration begun in July of 2013 to assess the value and clinical utility of FHACT™ in India.
Kamineni Hospitals will be offering the test in conjunction with Pap smear and HPV testing, and believes that the test will allow for more wide-spread, early detection of cervical cancer.
CGI’s FHACT test doesn’t require additional patient visits to the doctor or laboratory and offers a significant advantage for predominantly rural populations in India and other developing countries, where access to healthcare providers is limited.
FHACT is a unique combination of four genomic biomarkers that can be used on remnant liquid pap cytology or on conventional Pap smear. In the US, the test is offered in CGI’s CLIA laboratory in New Jersey and is intended to help in the triaging associated with the diagnosis and management of the approximately 3.5 million abnormal Pap smears in the US.